3SBio Inc. (TRSBF)

Market Cap	5.79B
Revenue (ttm)	1.25B
Net Income (ttm)	286.38M
Shares Out	n/a
EPS (ttm)	0.12
PE Ratio	20.23
Forward PE	17.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	182
Open	2.900
Previous Close	0.828
Day's Range	2.900 - 2.900
52-Week Range	0.723 - 3.000
Beta	0.71
RSI	93.93
Earnings Date	May 9, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5,577
• Stock Exchange: OTCMKTS
• Ticker Symbol: TRSBF

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY